Hemorrhagic cystitis in gastric cancer after nanoparticle albumin-bound paclitaxel: A case report

doi:10.4251/wjgo.v16.i3.1084

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4065)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series.

Item

Count

PDF

161

WORD

HTML

2037

Figures (1-3)

434

Sum=2632

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

299

Download

983

Sum=1282

Mar 15, 2024 (publication date) through Mar 3, 2026

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastrointest Oncol. Mar 15, 2024; 16(3): 1084-1090
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.1084

Hemorrhagic cystitis in gastric cancer after nanoparticle albumin-bound paclitaxel: A case report

Xin-Jie Zhang, Jian Lou

Xin-Jie Zhang, Jian Lou, Department of Cancer Center, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, Zhejiang Province, China

Author contributions: Zhang XJ collected data and drafted the manuscript; Lou J revised and finalized the manuscript; all authors have read and approved the final manuscript.

Informed consent statement: Written informed consent was obtained from the patient for publication of this report and any accompanying images.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Corresponding author: Jian Lou, MM, Chief Physician, Department of Cancer Center, The Fifth Affiliated Hospital of Wenzhou Medical University, No. 289 Kuocang Road, Liandu District, Lishui 323000, Zhejiang Province, China. 19994454@qq.com

Received: December 24, 2023
Peer-review started: December 24, 2023
First decision: January 10, 2024
Revised: January 18, 2024
Accepted: January 27, 2024
Article in press: January 27, 2024
Published online: March 15, 2024
Processing time: 78 Days and 18.6 Hours

Abstract

BACKGROUND

The advanced first-line regimen for advanced gastric cancer is based on a combination of fluoropyrimidine and platinum and/or paclitaxel (PTX), forming a two- or three-drug regimen. Compared to conventional PTX, nanoparticle albumin-bound PTX (Nab-PTX) has better therapeutic effects and fewer adverse effects reported in studies. Nab-PTX is a great option for patients presenting with advanced gastric cancer. Herein, we highlight an adverse event (hemorrhagic cystitis) of Nab-PTX in advanced gastric cancer.

CASE SUMMARY

A 55-year-old male was diagnosed with lymph node metastasis after a laparoscopic-assisted radical gastrectomy for gastric cancer that was treated by Nab-PTX and S-1 (AS). On the 15^th day after treatment with AS, he was diagnosed with hemorrhagic cystitis.

CONCLUSION

Physicians should be aware that hemorrhagic cystitis is a potential adverse event associated with Nab-PTX treatment.

Keywords: Nanoparticle albumin-bound paclitaxel; Hemorrhagic cystitis; Gastric cancer; Adverse event; Case report

Core Tip: Chemotherapy is an important treatment method for advanced gastric cancer. Up to now, nanoparticle albumin-bound paclitaxel (Nab-PTX) has shown promising responses in advanced gastric cancer. We aim to draw attention to a rarely treatment-related adverse event after Nab-PTX.